Fluidigm, a California-based life science research device provider, has filed with the SEC to become public this morning. The offering shows a total proposed maximum aggregate price of $86,250,000. They applied to trade on the Nasdaq Global Market under the ticker “FLDM.” The book-running managers are listed as Morgan Stanley, UBS Investment Bank, and Leerink Swann.
Fluidigm develops and manufactures their proprietary Integrated Fluidic Circuit system that improves the productivity in life science research by allowing researches to perform thousands of precise biochemical measurements on very small amounts of matter. They believe their product has the flexibility to be used in a variety of science sectors and overcomes other existing microwell-based systems.
The company posted product revenues of $3.9 million and $4.4 million in 2006 and 2007, respectively. However, due to high production, research and development, and other expenses, the company showed net losses of $23.5 and $25.4 in 2006 and 2006, respectively.
You can join our open email distribution list to hear about IPO’s, special financings, secondary offerings, M&A, and more previews for other special situations in various stages.
April 14, 2008